display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
mNSCLC - L1 - all populationmNSCLC - L1 - PDL1 positivemNSCLC - L1 - TMB>10Mb
nivolumab plus ipilimumab CheckMate 227 ... CheckMate 227 ...
nivolumab plus ipilimumab plus SoC CheckMate 9LA

Study type: